SCHEMBL1049417

SCHEMBL1049417

COCCOc1cccc2ccc(CC(CO)C(C)C)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.40
CYP3A4 P08684 1/20 0.40
KDM1A O60341 1/20 0.39
HTR1B P28222 7/20 0.39
NR2E1 Q9Y466 2/20 0.38
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 3/20 0.37
REN P00797 3/20 0.36
HTR1D P28221 2/20 0.36
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SLC6A4 P31645 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049210 0.88 KDM1A (0.39) KDM1AHTR1BNR2E1RENHTR1D
SCHEMBL5048053 0.84 REN (0.40) KMT2AREN
SCHEMBL1051243 0.83 KDM1A (0.44) KDM1AHTR1BKDM4EMEN1KMT2A
SCHEMBL1047493 0.82 PPARA (0.41) KDM1AHTR1BKDM4EKMT2AALDH1A1
SCHEMBL1050049 0.81 REN (0.38) REN
SCHEMBL1049937 0.80 REN (0.43) REN
SCHEMBL1051654 0.79 CAPN1 (0.40) KMT2AALDH1A1RENGAAMAPT
SCHEMBL5710620 0.79 HRH3 (0.41) CYP3A4KDM4EMEN1KMT2ACYP1A2
SCHEMBL1050592 0.78 KDM1A (0.44) KDM1AHTR1BHTR1DSLC6A4HRH1
SCHEMBL5710618 0.77 HRH3 (0.39) RENMAPTHTR2AHTR2BSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868036-B2 Organic compounds NOVARTIS AG (CH) 2011-01-11 US disclosed
US-20080058320-A1 Organic Compounds NOVARTIS AG (CH) 2008-03-06 US disclosed
EP-1725530-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-11-29 EP disclosed
WO-2005090304-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058320-A1 Organic Compounds REN, AGTR1, ADH1C MMP1 1508/4885CYP3A4 96/4885KDM1A 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.